Protalix Biotherapeutics Non Current Liabilities Total Over Time
| PLX Stock | USD 1.69 0.03 1.81% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Protalix Biotherapeutics Performance and Protalix Biotherapeutics Correlation. Protalix |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. If investors know Protalix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protalix Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.39) | Earnings Share (0.15) | Revenue Per Share 0.522 | Quarterly Revenue Growth (0.62) | Return On Assets (0.10) |
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protalix Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protalix Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protalix Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Non Current Liabilities Total Analysis
Compare Protalix Biotherapeutics and related stocks such as Corvus Pharmaceuticals, Aldeyra, and Gamida Cell Non Current Liabilities Total Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRVS | 10 M | 10 M | 10 M | 10 M | 10 M | 126.5 M | 1.4 M | 971 K | 869 K | 2.3 M | 1.2 M | 2.6 M | 1.4 M | 0.0 | 0.0 |
| ALDX | 26.8 M | 26.8 M | 26.8 M | 1.5 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 0.0 | 14.5 M | 11.4 M | 15.6 M | 14.9 M | 6.3 M | 8.8 M |
| CKPT | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 0.0 | 0.0 | 0.0 | 3.9 M | 7.2 M | 17.2 M | 20.3 M | 0.0 | 0.0 |
| CDTX | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 34 K | 6.1 M | 9.9 M | 7.2 M | 81 K | 942 K | 11.1 M | 19.7 M | 20.5 M | 7.8 M | 8.5 M |
| AKBA | 8 K | 8 K | 8 K | 8 K | 32 K | 74 K | 117.8 M | 100.6 M | 94.9 M | 168.3 M | 209.4 M | 192.6 M | 217.7 M | 172.4 M | 127.4 M |
| XFOR | 37.2 M | 37.2 M | 37.2 M | 37.2 M | 37.2 M | 37.2 M | 52.1 M | 14.9 M | 9 M | 22 M | 38.1 M | 38.7 M | 59.2 M | 73.3 M | 42.1 M |
| MCRB | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 139 M | 586 K | 109.6 M | 97.2 M | 126.5 M | 134.8 M | 121.8 M | 141.1 M | 252.4 M | 304.8 M | 320 M |
| PDSB | 22.3 M | 22.3 M | 22.3 M | 22.3 M | 41 M | 3 M | 15 M | 17.4 M | 0.0 | 1.2 M | 490.4 K | 231.4 K | 23.2 M | 19.6 M | 10.4 M |
| ELEV | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 97.2 M | 8 K | 29.4 M | 30.1 M | 26.2 M |
| LXRX | 3.5 M | 108 M | 86.8 M | 84.7 M | 142.4 M | 246 M | 153.6 M | 260.3 M | 273.8 M | 235.3 M | 611 K | 1.2 M | 54 M | 104.8 M | 100.6 M |
| IOVA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 230 K | 6.6 M | 57.1 M | 66.5 M | 84.4 M | 85.4 M | 89.7 M |
Protalix Biotherapeutics and related stocks such as Corvus Pharmaceuticals, Aldeyra, and Gamida Cell Non Current Liabilities Total description
My Equities
My Current Equities and Potential Positions
| Protalix Biotherapeutics | PLX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Israel |
| Exchange | NYSE MKT Exchange |
USD 1.69
Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.